Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Massachusetts General Hospital
Massachusetts General Hospital
University of Washington
University of California, Davis
Dana-Farber Cancer Institute
MEI Pharma, Inc.
Academic and Community Cancer Research United
Altor BioScience
Ipsen
Swiss Cancer Institute
SecuraBio
SecuraBio
University of Nebraska
Washington University School of Medicine
University of Washington
Swiss Cancer Institute
MEI Pharma, Inc.
Medical College of Wisconsin
University of Southampton
Spectrum Pharmaceuticals, Inc
Hoffmann-La Roche
Spectrum Pharmaceuticals, Inc
Northwestern University
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Northwestern University
Seagen Inc.
Gilead Sciences
Barbara Ann Karmanos Cancer Institute
Seagen Inc.
Gilead Sciences
Gilead Sciences
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
The Lymphoma Academic Research Organisation
Pfizer
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of Miami
Beth Israel Deaconess Medical Center
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
CTI BioPharma
National Cancer Institute (NCI)
Duke University
Janssen-Cilag G.m.b.H
Sanofi